Chief Operating Officer Ivy Brain Tumor Center / Barrow Neurological Institute, Arizona
High failure rate of clinical trials for glioblastoma treatment can be attributed, in part, to inaccuracies arising from preclinical investigations. Preclinical studies focused on the assessment of neuro- pharmacokinetics (PK) and pharmacodynamics (PD) play a pivotal role in identifying promising drug targets for further clinical investigation. This presentation aims to elucidate the existing challenges in translating preclinical findings to the clinic and delineate preclinical study strategies to promote promising drug candidates for GBM clinical trials.
Learning Objectives:
• Recognize the challenges in translating preclinical studies into the clinic.
• Identify PK/PD-based preclinical study designs to inform tissue-based clinical trials for GBM patients.
• Understand the limitations of preclinical modeling and recognize the need for PK/PD-driven clinical trials for brain tumors.
